相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis
Xiuyuan Zhao et al.
JOURNAL OF NEUROLOGY (2021)
Rimegepant Orally Disintegrating Tablet for Acute Migraine Treatment: A Review
Alicia Potter DeFalco et al.
ANNALS OF PHARMACOTHERAPY (2021)
Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine
William Kielbasa et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2020)
Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine
Jan Lewis Brandes et al.
CEPHALALGIA (2020)
Profiling lasmiditan as a treatment option for migraine
Martina Curto et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies
Tina M. Oakes et al.
HEADACHE (2020)
Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial
Abhijeet Jakate et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males
Wendy Ankrom et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2020)
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial
Jessica Ailani et al.
HEADACHE (2020)
Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials
Yanbo Yang et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
Vincent Martin et al.
ADVANCES IN THERAPY (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine
James M. Martinez et al.
CEPHALALGIA (2020)
Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials
Yanbo Yang et al.
CNS DRUGS (2020)
Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine: Evidence From Randomized Controlled Trials
Bixi Gao et al.
FRONTIERS IN PHARMACOLOGY (2020)
Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses
Jill Fiedler-Kelly et al.
HEADACHE (2020)
Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol
Max Tsai et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Lasmiditan: Its Development and Potential Use
Amanda E. Macone et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)
Headache medication and the COVID-19 pandemic
Antoinette MaassenVanDenBrink et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials
Bixi Gao et al.
FRONTIERS IN NEUROLOGY (2020)
Interpretation of Drug Interaction Using Systemic and Local Tissue Exposure Changes
Young Hee Choi
PHARMACEUTICS (2020)
Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
Richard B. Lipton et al.
NEUROLOGY (2020)
The locus of action of CGRPergic monoclonal antibodies against migraine: peripheral over central mechanisms
Abimael González-Hernández et al.
CNS & Neurological Disorders-Drug Targets (2020)
Lasmiditan in patients with common migraine comorbidities: apost hocefficacy and safety analysis of two phase 3 randomized clinical trials
David B. Clemow et al.
CURRENT MEDICAL RESEARCH AND OPINION (2020)
Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?
David Moreno-Ajona et al.
CURRENT OPINION IN NEUROLOGY (2020)
Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache
Lesley J. Scott
DRUGS (2020)
Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans
Abhijeet Jakate et al.
HEADACHE (2020)
Pain Freedom at 2 to 8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant
Erin G. Doty et al.
HEADACHE (2020)
Lasmiditan mechanism of action - review of a selective 5-HT1Fagonist
David B. Clemow et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis
Min Hou et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials
Virginia L. Stauffer et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Yanbo Yang et al.
CNS DRUGS (2020)
Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
Gary Berman et al.
HEADACHE (2020)
Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
Wim M. Mulleners et al.
LANCET NEUROLOGY (2020)
The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
Anna Vaisman-Mentesh et al.
FRONTIERS IN IMMUNOLOGY (2020)
The role of erenumab in the treatment of migraine
Anna P. Andreou et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2020)
Galcanezumab in migraine prevention: a systematic review and meta-analysis of randomized controlled trials
Panagiotis Gklinos et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2020)
An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
Ivan Urits et al.
PAIN AND THERAPY (2020)
Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine
Brian Baker et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2020)
Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
Hans-Christoph Diener et al.
CEPHALALGIA (2019)
Pharmacokinetics and pharmacodynamics of new acute treatments for migraine
Chiara Lupi et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2019)
Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure
Dustin D. Ruff et al.
CEPHALALGIA (2019)
Gepants for the treatment of migraine
Andrea Negro et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice
James Francescangeli et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Optimising migraine treatment: from drug-drug interactions to personalized medicine
Leda Marina Pomes et al.
JOURNAL OF HEADACHE AND PAIN (2019)
New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies
Damiana Scuteri et al.
FRONTIERS IN PHARMACOLOGY (2019)
Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN
John H. Krege et al.
CEPHALALGIA (2019)
The treatment efficacy of galcanezumab for migraine: A meta-analysis of randomized controlled trials
Zhouming Ren et al.
CLINICAL NEUROLOGY AND NEUROSURGERY (2019)
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials
Li Shen Loo et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
Robert Croop et al.
LANCET (2019)
Rimegepant oral disintegrating tablet for migraine
Lars Edvinsson
LANCET (2019)
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
Richard B. Lipton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine
Jill B. Fiedler-Kelly et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults
Peter J. Goadsby et al.
CEPHALALGIA (2019)
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
Michel D. Ferrari et al.
LANCET (2019)
Monoclonal antibodies for the prevention of migraine
Bianca Raffaelli et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine The ACHIEVE II Randomized Clinical Trial
Richard B. Lipton et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Migraine Epidemiology, Burden, and Comorbidity
Rebecca C. Burch et al.
NEUROLOGIC CLINICS (2019)
The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice
Kathleen B. Digre
HEADACHE (2019)
Erenumab safety and efficacy in migraine A systematic review and meta-analysis of randomized clinical trials
Changyu Zhu et al.
MEDICINE (2019)
Eptinezumab for the treatment of migraine
D. Scuteri et al.
DRUGS OF TODAY (2019)
New strategies for migraine treatment and prevention
Waldemar Brola et al.
AKTUALNOSCI NEUROLOGICZNE (2019)
Fremanezumab for the prevention of chronic and episodic migraine
L. Lionetto et al.
DRUGS OF TODAY (2019)
The pharmacology and therapeutic applications of monoclonal antibodies
Maria Sofia Castelli et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2019)
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
Vladimir Skljarevski et al.
CEPHALALGIA (2018)
A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
Orit Cohen-Barak et al.
CEPHALALGIA (2018)
Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults
Cristina Tassorelli et al.
CEPHALALGIA (2018)
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
David W. Dodick et al.
CEPHALALGIA (2018)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Targeted 5-HT1F Therapies for Migraine
Marta Vila-Pueyo
NEUROTHERAPEUTICS (2018)
The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy
Bianca Raffaelli et al.
NEUROTHERAPEUTICS (2018)
Lasmiditan is an effective acute treatment for migraine A phase 3 randomized study
Bernice Kuca et al.
NEUROLOGY (2018)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Design and engineering of deimmunized biotherapeutics
Karl E. Griswold et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2016)
Drug-Drug Interactions in Headache Medicine
Hossein Ansari et al.
HEADACHE (2016)
Immunogenicity and other problems associated with the use of biopharmaceuticals
Michael G. Tovey et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2011)
分享论文
